Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer

Journal of Magnetic Resonance Imaging

Volumn 16, Issue 4, 2002, Pages 451-463

  Kurhanewicz, John ^a   Swanson, Mark G ^a   Nelson, Sarah J ^a   Vigneron, Daniel B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Choline; Citrate; Hormone deprivation therapy; HR MAS; Magnetic resonance imaging (MRI); Magnetic resonance spectroscopic imaging (MRSI); Polyamines; Prostate cancer; Prostate specific antigen (PSA); Radiation therapy

Indexed keywords

CHOLINE; CITRIC ACID; GLYCEROPHOSPHOETHANOLAMINE; GLYCEROPHOSPHORYLCHOLINE; INOSITOL; LACTIC ACID; PHOSPHATIDYLETHANOLAMINE; PHOSPHORYLCHOLINE; POLYAMINE; PROSTATE SPECIFIC ANTIGEN; SPERMINE; TUMOR MARKER;

CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CRYOSURGERY; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLITE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PROSTATE; PROSTATIC NEOPLASMS;

EID: 0036794336     PISSN: 10531807     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmri.10172     Document Type: Review

References (104)

1. American Cancer Society Website: www.cancer.org. American Cancer Society Inc. Surveillance Research, 2002.
2. Han M, Partin AW, Piantadosi S, Epstein JI, Walsh PC. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate Cancer. J Urol 2001;166:416-419.
3. Stamey TA. Cancer of the prostate: an analysis of some important contributions and dilemmas. Mono Urol 1982;3:67-94.
4. McNeal JE, Kindrachuk RA, Freiha FS, Bostwick DG, Redwine EA, Stamey TA. Patterns of progression in prostate cancer. Lancet 1986;1:60-63.
5. Quinlan DM, Partin AW, Walsh PC. Can aggressive prostatic carcinomas be identified and can their natural history be altered by treatment? Urology 1995;46:77-82.
6. Jewett HJ. The present status of radical prostatectomy for stages A and B prostatic cancer. Urol Clin North Am 1975;2:105-124.
7. Lee WR, Hanks GE, Hanlon A. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. J Clin Oncol 1997;15:230-238.
8. Johansson JE, Adami HO, Andersson SO, Bergstrom R, Holmberg L, Krusemo UB. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA 1992;267:2191-2196.
9. Krongrad A, Lai H, Lai S. Variation in prostate cancer survival explained by significant prognostic factors. J Urol 1997;158:1487-1490.
10. Moul JW. Hormonal therapy options for biochemical recurrence of prostate cancer after local therapy. Mol Urol 2000;4:267-271; discussion 273.
11. D'Amico AV, Whittington R, Malkowicz SB, et al. Combination of the preoperative PSA level, biopsy gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer. Urology 2000;55:572-577.
12. Blackwell KL, Bostwick DG, Myers RP, Zincke H, Oesterling JE. Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density. J Urol 1994;151:1565-1570.
13. Akimoto S, Masai M, Akakura K, Shimazaki J. Tumor marker doubling time in patients with prostate cancer: determination of prostate-specific antigen and prostatic acid phosphatase doubling time. Eur Urol 1995;27:207-212.
14. Tsuji M, Murakami Y, Kanayama H, Sano T, Kagawa S. Immunohistochemical analysis of Ki-67 antigen and Bcl-2 protein expression in prostate cancer: effect of neoadjuvant hormonal therapy. Br J Urol 1998;81:116-121.
15. Keshgegian AA, Johnston E, Cnaan A. Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma. Am J Clin Pathol 1998;110:443-449.
16. Moul JW, Bettencourt MC, Sesterhenn IA, et al. Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery 1996;120:159-166; discussion 166-157.
17. Moul JW. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. Eur Urol 1999;35:399-407.
18. Ahlgren G, Pedersen K, Lundberg S, Aus G, Hugosson J, Abrahamsson PA. Tumor cell proliferation in prostate cancer after 3 months of neoadjuvant LHRH analogue treatment is a prognostic marker of recurrence after radical prostatectomy. Urology 1999;54:329-334.
19. Bonkhoff H, Fixemer T, Remberger K. Relation between Bcl-2, cell proliferation, and the androgen receptor status in prostate tissue and precursors of prostate cancer. Prostate 1998;34:251-258.
20. Carroll PR, Presti JJ, Small E, Roach MR. Focal therapy for prostate cancer 1996: maximizing outcome. Urology 1997:84-94.
21. Crawford ED, Fair WR, Kelloff GJ, et al. Chemoprevention of prostate cancer: guidelines for possible intervention strategies. J Cell Biochem Suppl 1992;16H:140-145.
22. Kurhanewicz J, Swanson MG, Wood PJ, Vigneron DB. Magnetic resonance imaging and spectroscopic imaging: improved patient selection and potential for metabolic intermediate endpoints in prostate cancer chemoprevention trials. Urology 2001;57:124-128.
23. Yu KK, Hricak H. Imaging prostate cancer. Radiol Clin North Am 2000;38:59-85.
24. Kurhanewicz J, Vigneron DB, Males RG, Swanson MG, Yu KK, Hricak H. The prostate: MR imaging and spectroscopy. Present and future. Radiol Clin North Am 2000;38:115-138.
25. Schnall MD, Lenkinski RE, Pollack HM, Imai Y, Kressel HY. Prostate: MR imaging with an endorectal surface coil. Radiology 1989;172:570-574.
26. Hricak H, White S, Vigneron D, et al. Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal-pelvic phased-array coils. Radiology 1994;193:703-709.
27. Sonnad SS, Langlotz CP, Schwartz JS. Accuracy of MR imaging for staging prostate cancer: a meta-analysis to examine the effect of technologic change. Acad Radiol 2001;8:149-157.
28. May F, Treumann T, Dettmar P, Hartung R, Breul J. Limited value of endorectal magnetic resonance imaging and transrectal ultrasonography in the staging of clinically localized prostate cancer. BJU Int 2001;87:66-69.
29. Yu KK, Scheidler J, Hricak H, et al. Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 1999;213:481-488.
30. Presti JJ, Hovey R, Carroll PR, Shinohara K. Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of nonpalpable and stage T1C carcinoma of the prostate. J Urol 1996;156:1685-1690.
31. Presti JJ, Hovey R, Bhargava V, Carroll PR, Shinohara K. Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of carcinoma of the prostate: ethnic variations. J Urol 1997;157:907-911: discussion 911-902.
32. Sommer FG, Nghiem HV, Herfkens R, McNeal J, Low RN. Determining the volume of prostate carcinoma: value of MR imaging with an external-array coil. AJR Am J Roentgenol 1993;161:81-86.
33. White S, Hricak H, Forstner R, et al. Prostate cancer: effect of postbiopsy hemorrhage on interpretation of MR images. Radiology 1995;195:385-390.
34. Hricak H. The prostate gland. In: Hricak H, Carrington BM, H, editors. MRI of the pelvis. London: Dunitz; 1991. p 249-311.
35. Scheidler J, Hricak H, Vigneron DB, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging-clinicopathologic study. Radiology 1999;213:473-480.
36. Star LJ, Vigneron DB, Pauly J, Kurhanewicz J, Nelson SJ. Improved solvent suppression and increased spatial excitation band-widths for three-dimensional PRESS CS1 using phase-compensating spectral/spatial spin-echo pulses. J Magn Reson Imaging 1997;7:745-757.
37. Star LJ, Nelson SJ, Kurhanewicz J, Huang LR, Vigneron DB. Improved water and lipid suppression for 3D PRESS CS1 using RF band selective inversion with gradient dephasing (BASING). Magn Reson Med 1997;38:311-321.
38. Schricker AA, Pauly JM, Kurhanewicz J, Swanson MG, Vigneron DB. Dualband spectral-spatial RF pulses for prostate MR spectroscopic imaging. Magn Reson Med 2001;46:1079-1087.
39. Kurhanewicz J, Vigneron DB, Hricak H, Narayan P, Carroll P, Nelson SJ. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology 1996;198:795-805.
40. Weider J, Schmidt G, Casola E, vanSonnenberg E, Stainken BF, Parsons CL. Transrectal ultrasound-guided transperineal cryoablation in the treatment of prostate carcinoma: preliminary results. J Urol 1995;154:435-441.
41. Costello LC, Franklin RB. Concepts of citrate production and secretion by prostate. I. Metabolic relationships. Prostate 1991;18:25-46.
42. Costello LC, Franklin RB. Concepts of citrate production and secretion by prostate. II. Hormonal relationships in normal and neoplastic prostate. Prostate 1991;19:181-205.
43. Kahn T, Beurrig K, Schmitz-Dreager B, Lewin JS, Feurst G, Meodder U. Prostatic carcinoma and benign prostatic hyperplasia: MR imaging with histopathologic correlation. Radiology 1989;173:847-851.
44. Schiebler ML, Tomaszewski JE, Bezzi M, et al. Prostatic carcinoma and benign prostatic hyperplasia: correlation of high-resolution MR and histopathologic findings. Radiology 1989;172:131-137.
45. Costello LC, Franklin RB. Novel role of zinc in the regulation of prostate citrate metabolism and its implications in prostate cancer. Prostate 1998;35:285-296.
46. Liang JY, Liu YY, Zou J, Franklin RB, Costello LC, Feng P. Inhibitory effect of zinc on human prostatic carcinoma cell growth. Prostate 1999;40:200-207.
47. Costello LC, Franklin RB. Bioenergetic theory of prostate malignancy. Prostate 1994;25:162-166.
48. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 1999;59:80-84.
49. Daly PF, Lyon RC, Faustino PJ, Cohen JS. Phospholipid metabolism in cancer cells monitored by 31P NMR spectroscopy. J Biol Chem 1987;262:14875-14878.
50. Cullis PR, Hope MJ. Physical properties and functional roles of lipids in membranes. In: Vance DE, Vance J, editors. Biochemistry of lipids, liproproteins and membranes. Amsterdam: Elsevier Science: 1991, p 1-41.
51. Mountford CE, Wright LC. Organization of lipids in the plasma membranes of malignant and stimulated cells: a new model. Trends Biochem Sci 1988;13:172-177.
52. Kurhanewicz J, Dahiya R, Macdonald JM, et al. Phosphorus metabolite characterization of human prostatic adenocarcinoma in a nude mouse model by 31P magnetic resonance spectroscopy and high pressure liquid chromatography. NMR Biomed 1992;5:185-192.
53. Kurhanewicz J, Dahiya R, Macdonald JM, Chang LH, James TL, Narayan P. Citrate alterations in primary and metastatic human prostatic adenocarcinomas: 1H magnetic resonance spectroscopy and biochemical study. Magn Reson Med 1993;29:149-157.
54. Kurhanewicz J, Vigneron DB, Nelson SJ, et al. Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. Urology 1995;45:459-466.
55. 1H NMR. Magn Reson Med 1992;25:140-147.
56. Cornel EB, Smits GA, Oosterhof GO, et al. Characterization of human prostate cancer, benign prostatic hyperplasia and normal prostate by in vitro 1H and 31P magnetic resonance spectroscopy. J Urol 1993;150:2019-2024.
57. Cai H, Erhardt P, Troppmair J, et al. Hydrolysis of phosphatidylcholine couples Ras to activation of Raf protein kinase during mitogenic signal transduction. Mol Cell Biol 1993;13:7645-7651.
58. Cuadrado A, Carnero A, Dolfi F, Jimenez B, Lacal JC. Phosphorylcholine: a novel second messenger essential for mitogenic activity of growth factors. Oncogene 1993;8:2959-2968.
59. Exton JH. Phosphatidylcholine breakdown and signal transduction. Biochim Biophys Acta 1994;1212:26-42.
60. Pelech SL, Vance DE. Signal transduction via phosphatidylcholine cycles. Trends Biochem Sci 1989;14:28-30.
61. Agris PF, Campbell ID. Proton nuclear magnetic resonance of intact Friend leukemia cells: phosphorylcholine increase during differentiation. Science 1982;216:1325-1327.
62. Carpinelli G, Podo F, Di VM, Proietti E, Gessani S, Belardelli F. Modulations of glycerophosphorylcholine and phosphorylcholine in Friend erythroleukemia cells upon in vitro-induced erythroid differentiation: a 31P NMR study. FEBS Lett 1984;176:88-92.
63. Galons JP, Fantini J, Vion DJ, Cozzone PJ, Canioni P. Metabolic changes in undifferentiated and differentiated human colon adenocarcinoma cells studied by multinuclear magnetic resonance spectroscopy. Biochimie 1989;71:949-961.
64. Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla AM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res 2001;61:3599-3603.
65. Kurhanewicz J, Vigneron DB, Nelson SJ. Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer. Neoplasia 2000;2:166-189.
66. Cheng LL, Wu CL, Smith MR, Gonzalez RG. Examining human prostate specimens with HRMAS 1H MR spectroscopy. In: Proceedings of the 7th Annual Meeting of ISMRM Philadelphia. 1999. p 114.
67. Cheng LL, Wu CL, Smith MR, Gonzalez RG. Non-destructive quantitation of spermine in human prostate tissue samples using HR-MAS H-1 NMR spectroscopy at 9.4 T. FEBS Lett 2001;494:112-116.
68. Schiebler ML, Miyamoto KK, White M, Maygarden SJ, Mohler JL. In vitro high resolution 1H-spectroscopy of the human prostate: benign prostatic hyperplasia, normal peripheral zone and adenocarcinoma. Magn Reson Med 1993;29:285-291.
69. Swanson MG, Males RG, Vigneron DB, et al. 1H HR-MAS spectroscopic analysis of post-surgical prostate tissue targeted using 3D MRI/MRS1. In: Proceedings of the 8th Annual Meeting of 1SMRM, Denver, 2000. p 97.
70. van der Graaf M, Schipper RG, Oosterhof GO, Schalken JA, Verhofstad AA, Heerschap A. Proton MR spectroscopy of prostatic tissue focused on the detection of spermine, a possible biomarker of malignant behavior in prostate cancer. MAGMA 2000;10:153-159.
71. Heby O. Role of polyamines in the control of cell proliferation and differentiation. Differentiation 1981;19:1-20.
72. Heston WD. Prostatic polyamines and polyamine targeting as a new approach to therapy of prostatic cancer. Cancer Surv 1991;11:217-238.
73. Swanson MG, Vigneron DB, Tran TK, Sailasuta N, Hurd RE, Kurhanewicz J. Single-voxel oversampled J-resolved spectroscopy of in vivo human prostate tissue. Magn Reson Med 2001;45:973-980.
74. Yu KK, Hricak H, Alagappan R, Chernoff D, Bacchetti P, Zaloudek C. Detection of extracapsular extension of prostate carcinoma by endorectal/phased array coil MR imaging: multivariate analysis, Radiology 1997;202:697-702.
75. Bostwick DG, Graham Jr, SD, Napalkov P, et al. Staging of early prostate cancer; a proposed tumor volume-based prognostic index. Urology 1993;41:403-411.
76. Stamey TA, McNeal JE, Freiha FS, Redwine E. Morphometric and clinical studies on 68 consecutive radical prostatectomies. J Urol 1988;139:1235-1241.
77. Coakley FV, Kurhanewicz J, Y. L, et al. Prostate cancer tumor volume: measurement by endorectal MR imaging and MR spectroscopic imaging. Radiology 2002;223:91-97.
78. Vigneron D, Males R, Hricak H, Noworolski S, Carrol PR, Kurhanewicz J. Prostate cancer: correlation of 3D MRS1 metabolite levels with histologic grade. In: Proceedings of RSNA, Chicago, 1998. p 181.
79. Wefer AE, Hricak H, Vigneron DB, et al. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology [see comments]. J Urol 2000;164:400-404.
80. Wefer AE, Hricak H, Okuno W, Carroll P, Kurhanewicz J. Magnetic resonance imaging and spectroscopy-targeted prostate biopsy. In: Proceedings of the 95th Meeting of the American Urological Association, Atlanta, 2000. p 211.
81. Zagars GK. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy. J Urol 1994;152:1786-1791.
82. 125iodine implantation for stage T1/T2 prostatic carcinoma. J Urol 1995;154:1096-1099.
83. Coakley FV, Hricak H, Wefer AE, Speight JL, Kurhanewicz J, Roach M. Brachytherapy for prostate cancer: endorectal MR imaging of local treatment-related changes. Radiology 2001;219:817-821.
84. Chen M, Hricak H, Kalbhen CL, et al. Hormonal ablation of prostatic cancer: effects on prostate morphology, tumor detection, and staging by endorectal coil MR imaging. AJR Am J Roentgenol 1996;166:1157-1163.
85. Parivar F, Hricak H, Shinohara K, et al. Detection of locally recurrent prostate cancer after cryosurgery: evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy. Urology 1996;48:594-599.
86. Parivar F, Kurhanewicz J. Detection of recurrent prostate cancer after cryosurgery: Curr Opin Urol 1998;8:83-86.
87. Mueller-Lisse UG, Vigneron DV, Hricak H, et al. Localized prostate cancer: effect of hormone deprivation therapy measured by combined three-dimensional IH-MR spectroscopy and MR imaging: clinico-pathologic case-control study. Radiology 2001;221:380- 390.
88. Mueller-Lisse UG, Swanson MG, Vigneron DB, et al. Time-dependent effects of hormone deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging. Magn Reson Med 2001;46:49-57.
89. Roach M, Kurhanewicz J, Carroll PR. Spectroscopy in prostate cancer; hope or hype? Oncology 2001;15;1399-1410.
90. Montironi R, Pomante R, Diamanti L, Magi-Galluzzi C. Apoptosis in prostatic adenocarcinoma following complete androgen ablation. Urol 1998;60(Suppl 1):25-29; discussion 30.
91. Roach M, Faillace-Akazawa P, Malfatti C, Holland J, Hricak H. Prostate volumes defined by magnetic resonance imaging and computerized tomographic scans for three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 1996;35:1011-1018.
92. Pickett B, Vigneault E, Kurhanewicz J, Verhey L, Roach M. Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy. Int J Radiat Oncol Biol Phys 1999;44:921-929.
93. Zaider M, Zelefsky MJ, Lee EK, et al. Treatment planning for prostate implants using magnetic-resonance spectroscopy imaging. Int J Radiat Oncol Biol Phys 2000;47:1085-1096.
94. Cheng LL, Lean CL, Bogdanova A, et al. Enhanced resolution of proton NMR spectra of malignant lymph nodes using magic-angle spinning. Magn Reson Med 1996;36:653-658.
95. Cheng LL, Ma MJ, Becerra L, et al. Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy. Proc Natl Acad Sci USA 1997;94:6408-6413.
96. Turnbull LW, Buckley DL, Turnbull LS, Liney GP, Knowles AJ. Differentiation of prostatic carcinoma and benign prostatic hyperplasia: correlation between dynamic Gd-DTPA-enhanced MR imaging and histopathology. J Magn Reson Imaging 1999;9:311- 316.
97. Padhani AR, Gapinski CJ, Macvicar DA, et al. Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol 2000;55:99-109.
98. Namimoto T, Morishita S, Saitoh R, Kudoh J, Yamashita Y, Takahashi M. The value of dynamic MR imaging for hypointensity lesions of the peripheral zone of the prostate. Comput Med Imaging Graph 1998;22:239-245.
99. Liney GP, Turnbull LW, Knowles AJ. In vivo magnetic resonance spectroscopy and dynamic contrast enhanced imaging of the prostate gland, NMR Biomed 1999;12:39-44.
100. Jager GJ, Ruijter ET, van de Kaa CA, et al. Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results. Radiology 1997;203:645-652.
101. Barentsz JO, Engelbrecht MR, Witjes JA, de la Rosette JJ, van der Graaf M. MR imaging of the male pelvis. Eur Radiol 1999;9:1722-1736.
102. Hosseinzadeh K, Read K, DiBiase S, Gullapalli R. Combined use of diffusion-weighted imaging (DWI) and MR spectroscopic imaging (MRSI) in the detection of prostate cancer for disease-targeted therapy. In: Proceedings of the 9th Annual Meeting of ISMRM 2001. Glasgow. Scotland. p 2343.
103. Scheidler J, Petsch R, Muller-Lisse U, Heuck AF, Reiser M. Echoplanar diffusion-weighted MR imaging of the prostate. In: Proceedings of the 7th Annual Meeting of ISMRM Philadelphia, 1999. p 1103.
104. Vigneron DB, Xu D, Chen AP, Swanson MG, Kurhanewicz J. Diffusion tensor imaging of the Prostate using single-shot fast spin echo. In: Proceedings of the 10th Annual Meeting of ISMRM, 2002, Honolulu. p 44.